Formulation of Cinnarizine for Stabilization of Its Physiologically Generated Supersaturation
- 98 Downloads
Physiologically generated supersaturation and subsequent crystallization of a weakly basic drug in the small intestine leads to compromised bioavailability. In this study, the pH-induced crystallization of cinnarizine (CNZ) in the presence of different polymers was investigated. Inhibitory effect of Eudragit L100 (Eu) on crystallization of CNZ at varying supersaturation ratios was examined. The effect of Eu on the dissolution behavior of CNZ from CNZ/Eu physical mixtures (PMs) and solid dispersions (SDs) was assessed. Results showed that both Eu and hydroxypropyl methylcellulose (HPMC) have a considerable maintenance effect on supersaturation of CNZ but Eu was more effective than HPMC. When Eudragit was used the phenomenon of liquid-liquid phase separation (formation of colloidal phase) was observed at supersaturation ratio of 20 times above the solubility of the drug. PMs showed a higher area under the dissolution curve (AUDC) compared with plain CNZ. In contrast, SDs showed a lower AUDC than plain CNZ. For SDs, the AUDC was limited by the slow release of the drug from Eu in acidic pH which in turn hindered the creation of CNZ supersaturation following the transition of acidic to neutral pH. From these findings, it can be concluded that the ability of the formulation to generate supersaturation state and also maintain the supersaturation is vital for improving the dissolution of CNZ.
KEY WORDSsupersaturation cinnarizine eudragit L100 hydroxypropyl methylcellulose crystallization inhibition dissolution
The financial support from Drug Applied Research Center of Tabriz.
University of Medical Sciences is greatly acknowledged.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Stahl HP, Nakano M. Pharmaceutical aspects of the drug salt form. In: Stahl PH, Wermuth CG, editors. Handbook of pharmaceutical salts: properties, selection, and use, 1st ed., Zurich. Switzerland: VHCA: Verlag Helvetica Chimica Acta; Weinheim, Federal Republic of Germany: Wiley-VCH; 2002. p. 83–116.Google Scholar
- 3.Hsieh YL, Ilevbare GA, Van Eerdenbrugh B, Box KJ, Sanchez-Felix MV, Taylor LS. pH-induced crystallization behavior of weakly basic compounds: determination of extent and duration of supersaturation using potentiometric titration and correlation to solid state properties. Pharm Res. 2012;29:2738–53. https://doi.org/10.1007/s11095-012-0759-8.CrossRefPubMedGoogle Scholar
- 8.Mellaerts R, Mols R, Kayaert P, Annaert P, Van Humbeeck J, Van den Mooter G, et al. Ordered mesoporous silica induces pH-independent supersaturation of the basic low solubility compound itraconazole resulting in enhanced transepithelial transport. Int J Pharm. 2008;357:169–79. https://doi.org/10.1016/j.ijpharm.2008.01.049.CrossRefPubMedGoogle Scholar
- 9.Miller JM, Beig A, Carr RA, Spence JK, Dahan A. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability. Mol Pharm. 2012;9:2009–16. https://doi.org/10.1021/mp300104s.CrossRefPubMedGoogle Scholar
- 13.Miller JM, Beig A, Krieg BJ, Carr RA, Borchardt TB, Amidon GE, et al. The solubility−permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation. Mol Pharm. 2011;8:1848–56. https://doi.org/10.1021/mp200181v.CrossRefPubMedGoogle Scholar
- 14.Vandecruys R, Peeters J, Verreck G, Brewster ME. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design. Int J Pharm. 2007;342:168–75. https://doi.org/10.1016/j.ijpharm.2007.05.006.CrossRefPubMedGoogle Scholar
- 15.Brewster ME, Vandecruys R, Verreck G, Peeters J. Supersaturating drug delivery systems: effect of hydrophilic cyclodextrins and other excipients on the formation and stabilization of supersaturated drug solutions. Pharmazie. 2008;63:217–20. https://doi.org/10.1691/ph.2008.7326.
- 24.Abu-Diak OA, Jones DS, Andrews GP. An investigation into the dissolution properties of celecoxib melt extrudates: understanding the role of polymer type and concentration in stabilizing supersaturated drug concentrations. Mol Pharm. 2011;8:1362–71. https://doi.org/10.1021/mp200157b.CrossRefPubMedGoogle Scholar
- 26.Savolainen M, Kogermann K, Heinz A, Aaltonen J, Peltonen L, Strachan C, et al. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy. Eur J Pharm Biopharm. 2009;71:71–9. https://doi.org/10.1016/j.ejpb.2008.06.001.CrossRefPubMedGoogle Scholar
- 30.Zimmermann A, Millqvist-Fureby A, Elema MR, Hansen T, Müllertz A, Hovgaard L. Adsorption of pharmaceutical excipients onto microcrystals of siramesine hydrochloride: effects on physicochemical properties. Eur J Pharm Biopharm. 2009;71:109–16. https://doi.org/10.1016/j.ejpb.2008.06.014.CrossRefPubMedGoogle Scholar
- 39.Raina SA, Van Eerdenbrugh B, Alonzo DE, Mo H, Zhang GGZ, Gao Y, et al. Trends in the crystallization and crystallization behavior of supersaturated aqueous solutions of poorly water-soluble drugs assessed using synchrotron radiation. J Pharm Sci. 2015;104:1981–92. https://doi.org/10.1002/jps.24423.CrossRefPubMedGoogle Scholar
- 40.Raina SA, Alonzo DE, Zhang GG, Gao Y, Taylor LS. Using environment-sensitive fluorescent probes to characterize liquid-liquid phase separation in supersaturated solutions of poorly water soluble compounds. Pharm Res. 2015;32:3660–73. https://doi.org/10.1007/s11095-015-1725-z.CrossRefPubMedGoogle Scholar
- 43.Heigoldt U, Sommer F, Daniels R, Wagner KG. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test. Eur J Pharm Biopharm. 2010;76:105–11. https://doi.org/10.1016/j.ejpb.2010.05.006.CrossRefPubMedGoogle Scholar
- 47.Guzmán HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR, et al. Combined use of crystalline salt forms and crystallization inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci. 2007;96:2686–702. https://doi.org/10.1002/jps.20906.CrossRefPubMedGoogle Scholar
- 54.Baghel S, Cathcart H, Redington W, O’Reilly NJ. An investigation into the crystallization tendency/kinetics of amorphous active pharmaceutical ingredients: a case study with dipyridamole and cinnarizine. Eur J Pharm Biopharm. 2016;104:59–71. https://doi.org/10.1016/j.ejpb.2016.04.017.CrossRefPubMedGoogle Scholar